Special thanks to our Platinum Sponsor Morgan Stanley
Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from firstname.lastname@example.org.
"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.
We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.
|Session Title||Start Time||End Time|
Lifting the Curtain on R&D to Advance New Drug Targets Faster
Science is driven by reproducible experimental evidence under peer-review toward global consensus, and it’s full of trial-and-error. There has been a push by some to make that research – successes and failures – more transparent to prevent others from making the same mistakes or going after the wrong targets. What can our innovation ecosystem do to share findings widely, challenge engrained beliefs, and follow new avenues, all while preserving a competitive advantage that academic and industry research require?
|8/26/2020 11:30 AM||8/26/2020 12:00 PM|
Realities of Precision Medicine – How Small is Too Small?
The world of precision medicine has evolved dramatically over the years, with targeted treatment for specific patients dating back 2,500 years to Hippocrates. Although genetic and biomarker testing to guide treatment is possible, and in theory should improve care while lowering costs, barriers to widespread adoption remain. Hear from expert panelists as they offer competing views on the shifting paradigm, from biohackers and ultra-rare disease, to more mainstream targeting. How small is too small?
|8/26/2020 1:00 PM||8/26/2020 1:30 PM|
AI and Drug Discovery: Marrying Data Science with Core Biology
Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating 'wet' in vitro/in vivo and 'dry' insilico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This panel will explore the new world of digital biology as a way to model potential drug effects more accurately and quickly.
|8/27/2020 10:15 AM||8/27/2020 10:45 AM|